|Bid||4.6700 x 3000|
|Ask||4.7000 x 3200|
|Day's Range||4.5400 - 4.9100|
|52 Week Range||1.8000 - 7.0700|
|Beta (5Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2020 - Aug 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.04|
ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
What happened Shares of ImmunoGen (NASDAQ: IMGN) were jumping 13.2% higher as of 3:11 p.m. EDT on Wednesday. The company didn't report any news. Instead, ImmunoGen's gains appeared to reflect continued interest from investors following the biotech's announcement last week of positive initial data from the Forward II phase 1/2b study evaluating mirvetuximab soravtansine in combination with Avastin as a treatment for ovarian cancer.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms' long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an "L"? We suggest taking a page from the analyst community's playbook.Using TipRanks' database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros' estimates. Here are seven of Wall Street's best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 13.) * AstraZeneca plc (NYSE: AZN) * AtriCure Inc. (NASDAQ: ATRC) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Catalent Inc (NYSE: CTLT) (announced a collaboration with Ennaid Therapeutics to develop an oral antiviral treatment targeted at COVID-19) * Co-Diagnostics Inc (NASDAQ: CODX) (reacted to disappointing sensitivity data reported by Abbott Laboratories (NYSE: ABT) for its rapid molecular testing for SARS-CoV-2) * CytomX Therapeutics Inc (NASDAQ: CTMX) * Forward Pharma A/S (NASDAQ: FWP) (announced extended timing for patent appeal) * Immunovant Inc (NASDAQ: IMVT) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Orgenesis Inc (NASDAQ: ORGS) (announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Translate Bio Inc (NASDAQ: TBIO) * Zai Lab Ltd (NASDAQ: ZLAB) (announced Chinese regulatory nod for its Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma and Optune monotherapy for recurrent glioblastoma) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech stocks that hit 52-week lows May 13.) * Genfit SA (NASDAQ: GNFT) * Recro Pharma Inc (NASDAQ: REPH) * Sensus Healthcare Inc (NASDAQ: SRTS) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN)Stocks In Focus ASCO Abstracts A slew of biotechs reacted to publication of online abstracts that are set to be presented at the 2020 American Society of Clinical Oncology Annual Virtual Meeting May 29-31.Updated safety and initial efficacy data for Arvinas Inc's (NASDAQ: ARVN) Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer showed two patients with ongoing confirmed prostate-specific antigen responses, including one with an unconfirmed partial tumor response.The stock was down 17.65% at $42 in Thursday's premarket session. Allogene Therapeutics Inc's (NASDAQ: ALLO) abstract consisted of first data from its Phase 1 dose escalation ALPHA study of CAR-T cell therapy ALLO-501 in relapsed/refractory non-Hodgkin lymphoma.Preliminary data on the first nine patients treated with escalating doses of ALLO-501 and a lower dose of ALLO-647 showed no dose limiting toxicities or graft-vs-host disease and a 78% overall response rate, with three complete responses and four partial responses.The stock was up 22.01% at $37.80 in the premarket session. ImmunoGen, Inc.'s (NASDAQ: IMGN) abstract consisted of initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin in patients with medium and high folate receptor alpha-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.The company said the combination showed promising anti-tumor activity and favorable tolerability, with a confirmed overall response rate of more than 60%.The stock was trading 5.39% higher at $4.30 in the premarket session. MEI Pharma Inc (NASDAQ: MEIP) announced updated data from a Phase 1b study of ME-401 in clinical development for the treatment of B-cell malignancies that showed treatment was generally well-tolerated, with an 83% overall response rate in patients with relapsed or refractory follicular lymphoma.MEI shares were up 2.47% at $2.90 premarket Thursday.MacroGenics Inc (NASDAQ: MGNX) announced preliminary results from two of its studies.The Phase 1 dose escalation and expansion clinical trial of MGD013 -- in combination with margetuximab, its investigational Fc-engineered monoclonal antibody targeting HER-2 -- suggested a response in approximately 40% of late-stage HER-2-positive tumors that compares favorably to low response rates for HER-2-directed agents and checkpoint blockades.Separately, the company announced early results from an ongoing Phase 1 study of MGC018, an ADC directed against B7-H3, showing preliminary signals of anti-tumor effects, including prostate-specific antigen reductions of 50% or more in five of seven patients with late-stage prostate cancer.The stock slumped 19.81% to $21.25 in after-hours trading.See also: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight CytomX announced further details of oral and poster presentations to be made at the month end's ASCO meeting.The stock was down 19.7% at $21.28 at the time of publication. Genocea Biosciences Inc (NASDAQ: GNCA) announced updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company's lead neo-antigen vaccine candidate, which showed that seven of the eight patients enrolled have continued without progression with a median follow-up of over one year.View more earnings on IBBThe stock was up 7.92% at $2.86 at the time of publication. Verona Pharma Receives Positive End-Of-Phase 2 Feedback From FDA VERONA PHARMA P/S' ADR (NASDAQ: VRNA) released details of the FDA's written response following the end-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease. The company said the response supported the continuation of its planned Phase 3 study. Verona expects to start the study in 2020.Verona shares were up 22.28% at $4.61 at the time of publication. Sanofi's Hemolysis Drug Accepted For Priority Review Sanofi SA (NASDAQ: SNY) said the FDA granted priority review of its BLA for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, or CAD. Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s. The PDUFA date has been set for Nov. 13.AIM ImmunoTech Gets FDA Nod For Starting Human Study of Combo Treatment In Cancer Patients With COVID-19 AIM ImmunoTech Inc (NYSE: AIM) said the FDA authorized the first human trial assessing the safety and effectiveness of its lead asset, Ampligen, in combination with interferon alfa-2b, in cancer patients with COVID-19.The stock was rallying by 36.17% to $3.20 in the premarket session. Illumima Marketing Chief To Depart Illumina, Inc.'s (NASDAQ: ILMN) global marketing head Omead Ostadan is leaving the company after more than a decade and is becoming president and COO of Seer Inc. effective June 29. Illumina shares were down 17.74% at $266.03 in the premarket session. Lilly, Innovent's Cancer Drug Aces Midphase Chinese Study In Esophageal Cancer Hong Kong biotech Innovent Biologics announced along with Eli Lilly And Co (NYSE: LLY) that the Phase 2 study of Tyvyt in China, dubbed ORIENT-2, met its primary endpoint of overall survival. The study evaluated Tyvyt monotherapy compared to chemotherapy as a second-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma.Biopharmx Shareholders Approve Reverse Merger With Timber Pharma Biopharmx Corp (NYSE: BPMX) announced that all proposals related to its proposed merger with Timber Pharmaceuticals were approved by stockholders at a special meeting held May 13. The company said it expects the deal to close on or about May 18,, contingent upon customary closing conditions and regulatory approvals.Upon closing of the transaction, the combined company will change its name to "Timber Pharmaceuticals, Inc." Its shares are expected to commence trading on the NYSE American market under the ticker symbol "TMBR."The stock was roaring higher by 40.46% to 66 cents in premarket trading Thursday. Applied DNA's COVID-19 Diagnostic Assay Kit Receives Emergency Use Authorization Applied DNA Sciences Inc (NASDAQ: APDN) said the FDA has issued Emergency Use Authorization, or EUA, for its Linea COVID-19 RT-PCR test to be performed in clinical labs in the U.S. certified under Clinical Laboratory Improvement Amendments to perform high complexity tests.Applied DNA shares were ripping 79.98% higher to $16 at the time of publication. Xeris Signs Distribution Deal Outside US For Low Blood Pressure Drug Xeris Pharmaceuticals Inc (NASDAQ: XERS) said it has signed an exclusive agreement with AIM-listed Clinigen Group to distribute its low blood pressure drug Gvoke outside of the U.S., where it is not currently licensed.Gvoke has not yet been approved in Europe.Immunic Gets Regulatory Nod For Phase 2 Study Of Coronavirus Drug Immunic Inc (NASDAQ: IMUX) said it has received the first regulatory approval from Germany's BfArM to initiate a Phase 2 study of its selective oral DHODH inhibitor, IMU-838, in COVID-19.The study is designed as a multicenter, randomized, placebo-controlled and double-blinded study, and it intends to study 230 patients with moderate COVID-19.The company said it expects to dose the first patient later this month and make top-line data from the study available later this year.In premarket trading Thursday, the stock was surging 19.84% to $12.20. Earnings RA Medical Systems Inc (NYSE: RMED) reported first-quarter revenue of $1.4 million, down from $1.7 million a year ago and lower than the $1.58-million consensus estimate.The loss widened from $1.16 per share to 56 cents per share, while analysts estimated a loss of 34 cents per share.The stock was declining 5.97% to 90 cents at the time of publication. Biocept Inc's (NASDAQ: BIOC) first-quarter revenue rose 41% year-over-year to $1.4 million. The loss per share narrowed from 61 cents to 11 cents.The stock was trading 4.83% higher to 46 cents in Thursday's premarket session. Offerings Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) priced its 2.4-million-share common stock offering at $18.25 per share. The company expects to raise gross proceeds of $75 million from the offering. The offering would close May 18.The stock was down 1% at $18.80 at the time of publication. Axcella Health Inc (NASDAQ: AXLA) priced its underwritten public offering of 11 million shares of its common stock at $4.75 per share to raise gross proceeds of $52.3 million. The offering is expected to close May 18.Axcella shares were down 0.56% at $5.31 premarket Thursday. On The Radar * Earnings * Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) * Kaleido Biosciences Inc (NASDAQ: KLDO) (before the market open) * Biomx Inc (NYSE: PHGE) (before the market open) * Soliton Inc (NASDAQ: SOLY) (before the market open) * ImmuCell Corporation (NASDAQ: ICCC) (before the market open) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) * Transenterix Inc (NYSE: TRXC) (before the market open) * Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) (before the market open) * Aptinyx Inc (NASDAQ: APTX) (after the close) * Aytu Bioscience Inc (NASDAQ: AYTU) (after the close) * Applied DNA (after the close) * INmune Bio Inc (NASDAQ: INMB) (after the close) * Dare Bioscience Inc (NASDAQ: DARE) (after the close) * Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (after the close) * Viveve Medical Inc (NASDAQ: VIVE) (after the close) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close) * Aptinyx Inc (NASDAQ: APTX) (after the close) * BioLife Solutions Inc (NASDAQ: BLFS) (after the close) * Co-Diagnostics (after the close) * Capricor Therapeutics Inc (NASDAQ: CAPR) (after the close) * Dyadic International, Inc. (NASDAQ: DYAI) (after the close) * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (after the close)Clinical Readouts Caladrius Biosciences Inc (NASDAQ: CLBS) will present at the Society for Cardiovascular Angiography and Intervention Virtual Conference, Scientific Sessions full data from the ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction.Constellation Pharmaceuticals Inc (NASDAQ: CNST) said abstracts of a presentation due at the June 11-14 European Hematology Association meeting will be made available. The abstract pertains to an interim update from the MANIFEST Phase 2 study that is evaluating CPI-0610 in myelofibrosis.Related Link: 5 Biopharmas Where BofA Would Put Its Money To Work See more from Benzinga * The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter * The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands 4M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status
ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference
ImmunoGen, Inc. (NASDAQ:IMGN) just released its latest quarterly report and things are not looking great. It looks...
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO, and Anna Berkenblit, our Chief Medical Officer. Dave Foster, our Chief Accounting Officer, will also join us for Q&A.
Shares of Immunogen (NASDAQ:IMGN) gained 10% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 43.33% over the past year to ($0.17), which missed the estimate of ($0.15).Revenue of $13,287,000 higher by 54.79% from the same period last year, which missed the estimate of $14,940,000.Outlook Immunogen hasn't issued any earnings guidance for the time being.Immunogen hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 01, 2020View more earnings on IMGNTime: 12:00 PM ETWebcast URL: https://edge.media-server.com/mmc/p/38zm7g3cRecent Stock Performance Company's 52-week high was at $7.07Company's 52-week low was at $1.76Price action over last quarter: down 30.78%Company Overview Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.See more from Benzinga * Recap: US Silica Holdings Q1 Earnings * Olympic Steel: Q1 Earnings Insights * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmarks ended were mixed on Friday, as investors' attention was fixed on the rising death toll in China and the limited strength displayed by American consumers last month.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Mark Enyedy became the CEO of ImmunoGen, Inc. (NASDAQ:IMGN) in 2016. First, this article will compare CEO compensation...